Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.

Leukemia & lymphoma - 1 Nov 2024

Yu Guopan, Zhang Weiguo, Basyal Mahesh, Nishida Yuki, Mizumo Hideaki, Ly Charlie, Zhang Hongying, Rice William G, Andreeff Michael

Abstract excerpt

Despite the development of several Fms-like tyrosine kinase 3 (FLT3) inhibitors that have improved outcomes in patients with FLT3-mutant acute myeloid leukemia (AML), drug resistance is frequently observed, which may be associated with the activation of additional pro-survival pathways, such as those regulated by BTK, aurora kinases (AuroK), and potentially others, in addition to acquired tyrosine kinase domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Aurora Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Protein-Tyrosine Kinases

Share to Tyrosine Kinase Inhibitors

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38871487
DOI: 10.1080/10428194.2024.2364839

Genes

FLT3
BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.PMID 38871487Read ↗

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinasesSemantic proximity Read ↗

Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.Semantic proximity Read ↗

The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.Semantic proximity Read ↗

The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.Semantic proximity Read ↗

Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.Semantic proximity Read ↗

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase InhibitorSemantic proximity Read ↗

Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).Semantic proximity Read ↗

Investigational drugs targeting FLT3 for leukemia.Semantic proximity Read ↗

Targeting FLT3 for the treatment of leukemia.Semantic proximity Read ↗

Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.Semantic proximity Read ↗

TP-0903 is active in models of drug-resistant acute myeloid leukemia.Semantic proximity Read ↗

FLT3 targeting in the modern era: from clonal selection to combination therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.